New Cancer Treatment Protocol: A Success!

 A groundbreaking hybrid protocol using repurposed drugs and nutrients left one man cancer-free after Stage 4 prostate cancer—at a fraction of standard treatment costs.

Mr. Jeffrey Kramer’s battle with Stage 4 metastatic prostate cancer is compelling and thought-provoking. It contrasts the bleak outlook of conventional “standard of care” treatments with the remarkable outcome of a low-cost, repurposed-drug-based protocol.

By anchoring the story in verifiable cancer statistics and clinical trial realities, it lends credibility and context before diving into the personal case. The article highlights the immense barriers that delay or block innovative treatments—particularly when profit incentives are absent—while also showing how global collaboration and alternative approaches can lead to breakthrough results.

The conclusion poses the essential challenge: should the U.S. health establishment fast-track trials and expand access, or continue with a slow, bureaucratic process that leaves patients without hope? The case of Mr. Kramer makes this question unavoidable.

• Cancer in America

  • 613,349 deaths in 2023; projected 618,000+ in 2025 (CDC).

  • 457 active NCI-supported protocols in databases.

  • Standard treatments often manage but rarely cure advanced cancers.

• The Patient: Jeffrey Kramer

  • Retired Ohio attorney diagnosed with Stage 4 metastatic prostate cancer in 2024.

  • Conventional prognosis: incurable, temporarily manageable with androgen-deprivation therapy.

  • Side effects of conventional drugs included rapid bone loss, fractures, and eventual decline.

• The Protocol

  • Published September 2024 in Journal of Orthomolecular Medicine.

  • “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment.”

  • Six key elements:

    1. Ketogenic diet.

    2. Moderate aerobic exercise.

    3. High-dose IV vitamin C.

    4. Daily ivermectin.

    5. Daily fenbendazole (or mebendazole).

    6. Daily vitamin/mineral supplementation with safety monitoring.

• Implementation

  • Supervised remotely by French researcher Pierrick Martinez.

  • Cleveland Clinic nutritionist advised on diet; nurse practitioner handled IV infusions.

  • Completed 15-week protocol in June 2025 with no side effects.

• Outcome

  • June 2025 PET scan showed no evidence of active cancer.

  • Total cost of treatment: under $20,000 (vs. $20K+ per month for standard care drugs).

• Broader Implications

  • Protocol not cancer-type specific; may benefit patients with immune systems damaged by conventional therapies.

  • Highlights systemic barriers: lack of Big Pharma profit motive delays trials by 10–20 years.

  • Raises ethical question: why prevent patients from accessing potentially life-saving protocols under supervised, experimental-use frameworks?

• Conclusion

  • Case suggests repurposed drugs could revolutionize cancer care.

  • Urges HHS to expedite trials, publicize findings, and allow supervised access.

  • Bottom line: patients with no alternatives “have nothing to lose.”

https://amgreatness.com/2025/09/05/new-cancer-treatment-protocol-a-success/